Genertec Universal Medical Group Company Limited (Stock Code: 2666) announced that its wholly-owned subsidiary, China Universal Leasing Co., Ltd. (the Issuer), plans to publicly issue the fourth tranche of corporate bonds (T4 Corporate Bonds) in the PRC. According to the announcement dated 1 December 2025, the Issuer’s corporate bond issuance was previously approved by the China Securities Regulatory Commission (CSRC) with a total principal amount of up to RMB8 billion. As of the issuance date, the outstanding principal of the corporate bonds stood at RMB5.4 billion.

The T4 Corporate Bonds, with a proposed principal amount not exceeding RMB1 billion, are expected to be issued off-line to qualified investors on the Shanghai Stock Exchange from 2 December 2025. These bonds will have a basic term of five years, featuring a repurchase option and a coupon rate adjustment option for the Issuer at the end of the third and fourth years. Investors will also have a sell-back option. The Issuer carries an AAA credit rating.

Relevant documents for the T4 Corporate Bonds will be published on the official website of the Shanghai Stock Exchange. The issuance of the Corporate Bonds is to be completed within 24 months from the date of the CSRC approval. The company will announce further progress on the remaining bonds as appropriate.